# TDM for Optimized Outcome in Patients With mRCC.

> **NCT04659343** · — · RECRUITING · sponsor: **Niels Fristrup** · enrollment: 200 (estimated)

## Conditions studied

- Kidney Cancer
- Renal Cell Carcinoma Metastatic
- Drug Toxicity
- Drug Side Effect
- Drug Mechanism

## Interventions

- **OTHER:** Measurement of concentration of active metabolite in cancer treatment.

## Key facts

- **NCT ID:** NCT04659343
- **Lead sponsor:** Niels Fristrup
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659343, "TDM for Optimized Outcome in Patients With mRCC.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04659343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*